Type A - Aflac Incorporated (AFL) 20261101 Stock Analysis

📅 Aflac Key Upcoming Events

• November 04, 2026 Q3 2026 Earnings Release (Confirmed)
  • Description: Aflac is scheduled to publish third-quarter financial results after the U.S. market closes, followed by its management webcast on November 5. Investors should focus on Japan’s premium trajectory, U.S. benefit ratios, investment income, adjusted EPS, and share repurchases. The release date was officially announced on September 30, 2026.

🏢 Step 1: Aflac Company Overview & Business Model

Q1-A1. What is Aflac?

• Company Name (Ticker): Aflac Incorporated (AFL)
• Sector: Financials
• Exchange: NYSE
• Founded: November 17, 1955
• Listing Date: March 17, 1974
• Fiscal Year End: December
• Headquarters: United States, Columbus, Georgia
• CEO: Daniel P. Amos
• Market Cap: $62.11B
• Shares Outstanding: 501.34M
• Current Stock Price: $123.89
• Annual Dividend Yield: 1.97%
• Ex-dividend Date: August 19, 2026 (ET, historical basis)
• As-of: November 01, 2026 (ET)

Q1-A2. How Does Aflac Make Money?

• Supplemental Insurance Premiums: Aflac primarily earns recurring premiums from supplemental health and life insurance policies sold to individuals and through workplace benefit programs in Japan and the United States. Its policies provide cash benefits for specified illnesses, accidents, hospitalizations, disability, and other insured events.
• Underwriting Profit: Aflac retains the difference between premiums collected and the combined costs of policyholder benefits, commissions, administration, and other insurance expenses. Product pricing, claims experience, policy persistency, and distribution efficiency determine sustainable underwriting profitability.
• Investment Portfolio Income: Premiums received before claims are paid create substantial investable assets. Aflac earns interest and investment returns on a portfolio supporting its insurance obligations, making interest rates, credit quality, asset-liability matching, and currency exposure important earnings drivers.
• Distribution Economics: In Japan, Aflac relies on established agency and financial-institution relationships. In the United States, employers, brokers, and benefits distributors provide access to policyholders seeking coverage that complements primary health insurance.

Q1-A3. Aflac’s Revenue Segments & Core Income Sources

• Aflac Japan — Approximately 51% of Q2 2026 Adjusted Revenues: The segment generated approximately $2.16B in adjusted revenue, including $1.54B of net earned premiums. Cancer, medical, nursing-care, and life insurance are central products. Japan is Aflac’s largest operating segment by adjusted revenue and an even larger contributor to segment pretax earnings.
• Aflac U.S. — Approximately 42% of Q2 2026 Adjusted Revenues: The segment generated approximately $1.77B, including $1.54B of net earned premiums. Products include accident, critical illness, disability, hospital indemnity, dental, and vision insurance. Workplace benefits penetration and new policy sales are important growth drivers.
• Corporate and Other — Approximately 7% of Q2 2026 Adjusted Revenues: This category generated approximately $291M and includes corporate investment income, certain insurance operations, financing costs, and other activities.
• Segment Mix Basis: The percentages use approximately $4.22B of Q2 2026 combined segment adjusted revenues before consolidation differences. They are operating-mix estimates rather than percentages of consolidated GAAP revenue of $4.12B.
• Profit Contribution: Japan generated $741M of Q2 pretax adjusted earnings versus $370M from the United States. Japan therefore contributed roughly two-thirds of positive operating-segment pretax adjusted earnings, highlighting the importance of its underwriting margin and currency exposure.

Q1-A4. Who Are Aflac’s Competitors?

• U.S. Supplemental Insurance Competitors: Unum, MetLife, Cigna’s supplemental-benefits offerings, and other workplace benefits providers compete through product features, broker relationships, underwriting standards, service quality, and employer distribution.
• Japanese Insurance Competitors: Japan Post Insurance, Dai-ichi Life, Japan’s major life insurers, and specialized medical and cancer insurance providers compete for household protection and savings-oriented insurance demand.
• Competitive Advantages: Aflac has a widely recognized brand, long-established Japanese distribution relationships, expertise in supplemental products, and an extensive existing policyholder base. These advantages support retention and distribution access but do not eliminate competitive pricing pressure.
• Substitute Products: Employer-funded benefits, medical expense savings, government health coverage, and comprehensive private insurance policies can reduce consumers’ demand for certain supplemental products.
• Industry Position: Aflac is a major incumbent in Japan’s cancer and medical supplemental insurance markets and a recognized U.S. workplace-benefits provider. Its advantages are more substantial in specialized distribution and product familiarity than in exclusive technology.

Q1-A5. Aflac Key Events: Past 12 Months

• December 2025 Introduced Anshin Palette Medical Insurance in Japan
  • Description: The new medical insurance product broadened Aflac Japan’s offering and helped support subsequent sales despite pressure from maturing legacy policies. Its contribution will depend on sustained new annualized premium sales and attractive lifetime underwriting economics.
• February 2026 Reported Full-Year 2025 Financial Results
  • Description: FY2025 revenue declined to approximately $17.16B from $18.93B in FY2024, while reported net income fell to approximately $3.65B. Investment-related fluctuations and foreign exchange effects complicate direct comparisons with recurring insurance earnings.
• August 06, 2026 Q2 2026 Earnings Release
  • Description: Total quarterly revenue declined 1.0% to $4.12B, while GAAP net earnings rose 37.7% to $825M. Adjusted earnings declined 7.7% to $883M, with adjusted diluted EPS of $1.75 versus $1.78 a year earlier. Aflac returned approximately $1.30B to shareholders through dividends and buybacks during the quarter.
• September 30, 2026 Announced Third-Quarter Earnings Release Schedule
  • Description: Aflac confirmed that Q3 results would be released on November 4. The disclosure establishes the next major opportunity to reassess underlying earnings trends, Japan’s policy sales, and U.S. claims experience.

Q1-A6. Step 1 Key Takeaways

• Step 1 Summary: Aflac combines an established supplemental insurance franchise in Japan and the United States with substantial investment income and disciplined shareholder distributions. Its central challenge is converting a mature Japanese insurance portfolio and growing U.S. business into consistent recurring earnings growth despite currency and claims volatility.

🏰 Step 2: Aflac’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does Aflac Have a Durable Economic Moat?

• Brand and Distribution Strength: Aflac’s long operating history, specialized product expertise, recognizable branding, and established agency relationships create meaningful barriers to rapid market-share displacement.
• Customer Retention: Japan’s 12-month premium persistency was 92.7% in Q2 2026, indicating substantial renewal stability, although this was below 93.7% a year earlier. U.S. persistency reached 79.4%, slightly above 79.2% a year earlier.
• Pricing Power: Insurance pricing is constrained by competition, regulation, consumer affordability, and the economics of existing policy contracts. Aflac can introduce repriced products and improve underwriting selection but cannot freely reprice every outstanding policy.
• Underwriting Advantages: Japan’s Q2 2026 benefit ratio improved to 64.0% from 66.5%, supporting underwriting economics. In contrast, the U.S. ratio rose to 49.5% from 47.3%, demonstrating that the moat does not fully protect against claims fluctuations.
• Moat Durability: Established distribution and policyholder relationships provide a durable competitive position, while mature end markets, lower-cost alternatives, and new insurance products limit the potential for sustained extraordinary growth.

Q2-A2. Is Aflac’s Growth Sustainable?

• Industry Structure and Outlook: Supplemental health insurance benefits from aging populations, medical-cost exposure, and employers’ interest in voluntary benefits. However, Japan’s aging and shrinking population, mature penetration, and policy replacement dynamics limit premium-volume growth.
• Growth Sustainability: Aflac’s most credible growth path combines modest U.S. premium expansion, improved product mix in Japan, higher-quality investment income, and sustained buybacks. This is a mature-compounding profile rather than rapid organic expansion.
• Downside Scenarios:
  • 1 Japanese premium contraction accelerates as older policies mature and new product sales cannot replace runoff, reducing recurring underwriting income.
  • 2 U.S. claim severity and benefit utilization rise faster than premium growth, weakening underwriting margins despite improved sales.
  • 3 A stronger U.S. dollar reduces translated Japanese profits while financial-market volatility produces investment losses and uneven capital generation.

Q2-A3. How Does Aflac Allocate Capital & Return Cash?

• Dividend Discipline: Aflac has established a multidecade record of annual dividend increases. The current indicated annual dividend is $2.44 per share, representing approximately 1.97% of the October 30 closing share price.
• Share Repurchases: During Q2 2026, Aflac repurchased $983M of shares and distributed $309M in dividends. Its outstanding share count decreased approximately 5.75% year over year, materially supporting EPS per share.
• Shareholder Yield: Annualizing Q2 repurchases and dividends implies a distribution pace above 8% of the current market capitalization, although the quarterly pace is not a guaranteed annual commitment.
• Reinvestment Priorities: Product development, distribution capabilities, technology, and insurance capital requirements compete with shareholder distributions. Capital deployment must preserve subsidiary solvency and support claims obligations.
• Capital Allocation Judgment: Aflac’s buyback execution is a major strength, but the value created depends on repurchase prices and the sustainability of underwriting capital generation.

Q2-A4. Step 2 Key Takeaways

• Scoring Rationale:
  • Economic Moat (8/10): Strong brand, distribution relationships, and policy retention support a durable competitive position, although pricing flexibility is limited.
  • Growth Sustainability (5/8): U.S. growth and product innovation provide opportunities, but Japan’s mature portfolio and currency exposure constrain expansion.
  • Capital Allocation (7/7): Substantial buybacks, a long dividend-growth record, and material share-count reduction demonstrate strong shareholder-oriented capital deployment.
• 📊 Step 2 Score: 20/25 pts (Economic Moat 8/10 + Growth Sustainability 5/8 + Capital Allocation 7/7)
• Step 2 Summary: Aflac’s strongest advantages are customer retention, specialized distribution, and capital allocation rather than rapid organic growth. Continued shareholder returns can sustain per-share value creation even when premium expansion remains modest.

💰 Step 3: Is Aflac Profitable? Financial Health Analysis

Q3-A1. Aflac’s Growth & Profitability Trends

• Revenue Recovery Is Uneven: Consolidated revenue declined from $18.93B in FY2024 to $17.16B in FY2025, then reached approximately $18.07B on a TTM basis through June 2026. Q2 2026 revenue nevertheless decreased 1.0% year over year, showing that reported TTM improvement does not establish broad-based accelerating premium growth.
• Reported Profit Rebounded More Than Underlying Profit: FY2025 operating income was approximately $4.75B versus $6.61B in FY2024. TTM operating income through June 2026 reached approximately $6.03B, while TTM net income was $4.86B and diluted EPS was $9.37. Investment gains and losses materially influence these reported figures.
• Adjusted Earnings Reveal a More Modest Trend: Q2 2026 adjusted earnings fell from $957M to $883M, while adjusted EPS declined only 1.7% to $1.75. For H1 2026, adjusted earnings declined approximately 4.2% to $1.78B, but adjusted diluted EPS increased 2.0% to $3.50, assisted by repurchases.
• Margin Performance Differs by Geography: Japan’s adjusted pretax margin improved from 32.0% to 34.3% in Q2, while the U.S. margin declined from 22.5% to 20.9%. Consolidated margin improvement is therefore not uniform across business lines.
• Cash Flow Has Weakened Over Several Years: Operating cash flow declined from $3.19B in FY2023 to $2.71B in FY2024 and $2.56B in FY2025, before reaching approximately $2.65B on a TTM basis through June 2026. Insurance cash flows require interpretation alongside reserves, investments, and policy liabilities.
• Operating Leverage Assessment: Japan demonstrated improved underwriting margins despite lower adjusted revenue, but rising U.S. benefits reduced profitability. Aflac’s per-share earnings stability reflects both operational performance and fewer outstanding shares.

Q3-A2. How Profitable Is Aflac? (Margins & ROIC)

• Return on Equity: Reported TTM ROE was approximately 16.9%, while annualized Q2 2026 adjusted ROE excluding foreign currency remeasurement was 16.6%. These figures indicate meaningful profitability on the company’s capital base, although their measurement definitions differ.
• Cost of Equity: A reasonable analytical cost-of-equity range is approximately 8-10%, reflecting a mature insurer’s business risk, equity-market exposure, and interest-rate sensitivity. Adjusted ROE above this range suggests positive economic value creation, subject to capital and accounting adjustments.
• Return on Assets: TTM ROA was approximately 3.1%, an insurance-relevant measure given the scale of invested assets and policyholder liabilities.
• Insurance Efficiency: Traditional industrial ROIC-WACC comparisons are less economically informative for an insurer. Underwriting margins, benefit ratios, investment spreads, reserve adequacy, solvency capital, and ROE provide more relevant evidence.
• Peer Position: Aflac’s profitability benefits from Japan’s relatively strong adjusted underwriting margins, while its geographic concentration and U.S. claims pressure create risks not necessarily shared equally by more diversified peers.

Q3-A3. What Drives Aflac’s Returns? (ROIC Breakdown)

• Selected Efficiency Indicators: Japan Benefit Ratio, U.S. Benefit Ratio, and Policy Persistency — these measures capture underwriting profitability and retention, which are more informative for Aflac than manufacturing-style asset turnover.
  • Japan Benefit Ratio Improved: The ratio declined to 64.0% in Q2 2026 from 66.5% a year earlier. Lower benefits relative to earned premiums helped lift Japan’s pretax adjusted margin.
  • U.S. Benefit Ratio Deteriorated: The ratio increased to 49.5% from 47.3%, reflecting claims growth faster than premiums and contributing to weaker adjusted pretax earnings.
  • Policy Persistency Shows Geographic Divergence: Japan persistency declined to 92.7% from 93.7%, while U.S. persistency improved modestly to 79.4% from 79.2%. Retention protects the premium base but remains sensitive to product mix and customer behavior.
• Operational Driver: Long-duration relationships, claims experience, new policy sales, product pricing, and investment yields jointly determine sustainable earnings.
• Return Driver Conclusion: Strong Japanese underwriting economics and sustained capital efficiency support ROE, while U.S. claims inflation and Japanese policy runoff limit the potential for broad profitability expansion.

Q3-A4. Are Aflac’s Earnings High Quality?

• GAAP Versus Adjusted Earnings: Q2 2026 GAAP earnings rose 37.7% while adjusted earnings declined 7.7%. The divergence was heavily influenced by lower investment losses, meaning reported growth substantially overstated improvement in recurring operations.
• Cash Conversion: TTM operating cash flow of approximately $2.65B divided by TTM net income of approximately $4.86B gives an OCF-to-net-income ratio of approximately 0.54x. FY2025’s corresponding ratio was approximately 0.70x.
• Insurance Accounting Context: Cash conversion is influenced by premium collection timing, benefit payments, investment activity, reserve changes, and the classification of insurance liabilities. An industrial company’s cash-conversion threshold should not be applied mechanically.
• Quality Judgment: Aflac’s underlying earnings are supported by durable premiums and investment income, but material investment-related adjustments and declining historical operating cash flow require careful normalization.

Q3-A5. Is Aflac’s Balance Sheet Healthy? (Debt & Leverage)

• Shareholder Equity: Total shareholders’ equity was approximately $30.31B at June 30, 2026, compared with $27.20B a year earlier.
• Financial Leverage: The standardized debt-to-equity ratio was approximately 0.53x, with debt-to-EBITDA near 2.65x. These consolidated metrics include financing and insurance-specific considerations and should not be interpreted as ordinary industrial leverage.
• Interest Coverage: Standardized EBIT-to-interest coverage was approximately 24.91x, suggesting substantial earnings coverage of financing expenses on that accounting basis.
• Insurance Capital: Insurance subsidiary solvency, investment liquidity, reserve sufficiency, and asset-liability matching matter more than a conventional current ratio. The reported asset base and recurring earnings support resilience, but not all invested assets are freely distributable to parent shareholders.
• Financial Stability: The evidence does not indicate an immediate financing or solvency crisis. The principal balance-sheet risks concern credit events, interest-rate movements, investment marks, and insurance liabilities rather than routine near-term debt service.

Q3-A6. Step 3 Key Takeaways

• Scoring Rationale:
  • Profitability·Capital Efficiency (8/10): Strong adjusted ROE and Japanese underwriting margins support profitability, offset by uneven operating growth.
  • Cash Flow·Profit Quality (5/8): Positive operating cash flow is established, but the historical decline and material GAAP adjustments weaken conversion quality.
  • Financial Soundness·Debt Management (6/7): Substantial equity and interest coverage support resilience, with exposure to investment and insurance reserve risks.
• 📊 Step 3 Score: 19/25 pts (Profitability·Capital Efficiency 8/10 + Cash Flow·Profit Quality 5/8 + Financial Soundness·Debt Management 6/7)
• Step 3 Summary: Aflac remains profitable and well capitalized on the available accounting measures. However, the difference between reported and adjusted earnings, weaker historical cash conversion, and geographic underwriting divergence warrant a measured financial-quality assessment.

🔎 Step 4: Aflac Forensic Accounting & Dilution Review

Q4-A1. Does Aflac Have Accounting Red Flags?

• Revenue recognition: not found
  • Evidence: The reviewed disclosures describe recurring insurance premiums and investment income. No specific material revenue-recognition irregularity was established, although insurance accounting estimates remain significant.
• Cost capitalization: not found
  • Evidence: Insurance acquisition costs and related amortization follow specialized accounting rules. The reviewed financial information did not establish improper capitalization, but acquisition-cost assumptions remain relevant to earnings quality.
• Sharp increase in accounts receivable and inventory: not found
  • Evidence: Inventory is not material to Aflac’s insurance business. TTM changes in accounts receivable were approximately -$50M in operating cash flow, without evidence of an extraordinary receivables buildup.
• Non-recurring adjustment (normalization): discovered
  • Evidence: Q2 2026 net investment losses of approximately $153M and differences between GAAP and adjusted earnings demonstrate material normalization needs. Reported net income should not be treated as an unadjusted measure of sustainable underwriting performance.

Q4-A2. Is Aflac Overspending? (Capex & Capital Cycle)

• ➖ Not applicable: Aflac’s principal capital commitments are insurance regulatory capital, investment assets, distribution, and product development rather than factories or commodity-producing capacity. Its relevant capital-cycle exposure concerns investment and underwriting conditions rather than physical oversupply from industrial capital expenditure.

Q4-A3. How Sound Is Aflac’s Cash Flow?

• Operating Cash Flow Pattern: Annual operating cash flow decreased from approximately $5.05B in FY2021 to $2.56B in FY2025, followed by approximately $2.65B on a TTM basis through June 2026. The multiyear decline deserves attention even though reported operating cash flow remains positive.
• Profit-to-Cash Gap: TTM operating cash flow of $2.65B represented approximately 54% of $4.86B in reported net earnings. Noncash investment movements, insurance liabilities, and other operating adjustments materially affect this relationship.
• Capital Distribution Pressure: Q2 distributions of $1.30B were substantial relative to the company’s quarterly operating cash generation. Sustaining elevated repurchases depends on subsidiary dividends, available capital, liquidity, and recurring earnings.
• Warning Assessment: Positive operating cash generation and meaningful equity provide support, but deteriorating multiyear cash conversion is a monitoring priority rather than evidence of nonexistent operating earnings.

Q4-A4. Is Aflac Diluting Shareholders?

• ⏪ Confirmed (Past) Dilution: Shares outstanding decreased approximately 5.75% year over year to 501.34M, driven by significant buybacks. The reduction in share count supported adjusted EPS despite lower total adjusted earnings.
• ⏩ Potential (Future) Dilution & Overhang: Equity compensation and routine employee-related issuances may create limited dilution, but no substantial near-term equity financing requirement was established. The principal shareholder-flow consideration is continued buyback execution, not a demonstrated large issuance overhang.

Q4-A5. Data Integrity Check

• Period: FY2025 annual, TTM through June 2026, and Q2 2026 quarterly observations are identified separately ➡ (Pass)
• Definition: GAAP earnings and company-adjusted operating earnings are distinguished; OCF is not represented as freely distributable insurance capital ➡ (Pass)
• Number of Shares: Current outstanding shares are distinguished from diluted weighted-average EPS denominators ➡ (Pass)
• Unit: Consolidated financial values are expressed in USD, with Japanese local-currency observations identified separately ➡ (Pass)
• Single Value Confirmation: The adopted financial periods, primary reported figures, and share-count definitions are internally consistent; standardized ratios retain their stated accounting limitations ➡ (Pass)

Q4-A6. Step 4 Key Takeaways

• Scoring Rationale:
  • Accounting anomalies·distortion signals (6/8): No specific fraud or recognition anomaly was established, but investment adjustments and insurance accounting complexity require normalization.
  • Cash flow warning signals (5/7): Cash flow remains positive, though its multiyear decline and weaker earnings conversion limit confidence.
  • Dilution factors (5/5): Repurchases materially reduced outstanding shares, with no established major equity-issuance overhang.
• 📊 Step 4 Score: 16/20 pts (Accounting anomalies·distortion signals 6/8 + Cash flow warning signals 5/7 + Dilution factors 5/5)
• Step 4 Summary: Aflac’s major forensic concern is earnings normalization and declining historical operating cash conversion, not demonstrated improper accounting or dilution. Share repurchases represent a clear positive offset.

👔 Step 5: Aflac Management & Shareholder Alignment

Q5-A1. Can You Trust Aflac’s Management? (Guidance Track Record)

• Leadership Continuity: Daniel P. Amos has led Aflac for decades, supporting continuity in corporate strategy, insurance distribution, and shareholder capital policy.
• Capital Allocation Execution: The company’s established dividend-growth history and sizable share repurchases support management credibility through observable actions.
• Operating Delivery: H1 2026 adjusted earnings declined 4.2%, while adjusted EPS rose 2.0% because of share-count reduction. This supports per-share capital management but does not demonstrate sustained growth in underlying aggregate operating earnings.
• Transparency: Management discloses both GAAP and adjusted results, alongside segment underwriting and currency metrics. The differences between these measures require investors to distinguish genuine operating progress from accounting and capital effects.

Q5-A2. What Are Aflac Insiders Doing?

• Director Transactions: Director Joseph L. Moskowitz sold 12,370 shares on June 22, 2026, at approximately $116.54 per share, alongside a reported 20,303-share option exercise. He also sold 600 shares on August 10 at approximately $124.10.
• Strategic Shareholder Transactions: Japan Post Holdings reported multiple share sales during June and September 2026, including 13,173 shares on September 11 at approximately $115.12 per share. These transactions should be separated from discretionary buying or selling by operating executives.
• Aggregate Flow: Retrieved transaction records show identifiable selling activity, but a complete comparable net share-flow total across all officers, directors, and reportable holders over the full trailing twelve months could not be established.
• Management Sentiment: The identified sales do not establish a coordinated executive exit or demonstrate that management considers the shares overvalued. Option exercises, compensation arrangements, and shareholder-specific portfolio management can affect transaction interpretation.

Q5-A3. Is Aflac’s Management Aligned With Shareholders?

• Governance Structure: Aflac’s ordinary common shares provide conventional public-company ownership exposure. No material dual-class voting arrangement was identified in the reviewed disclosures.
• Capital Return Alignment: Repurchases and growing dividends directly benefit shareholders, particularly when buybacks occur at economically attractive valuations.
• Compensation Incentives: Long-term equity incentives can align executives with shareholders, although incentives based primarily on per-share measures may reward repurchases without equivalent growth in underlying aggregate earnings.
• Governance Assessment: Management continuity and demonstrated shareholder distributions are strengths; oversight of succession, underwriting quality, and investment risk remains essential.

Q5-A4. Step 5 Key Takeaways

• Scoring Rationale:
  • Management Trust (4/5): Long leadership continuity and demonstrated capital distributions support credibility, with modest organic earnings performance limiting the assessment.
  • Insider Trends (3/5): Documented insider-related sales provide no clear bullish accumulation signal, while transaction motivations and full-period aggregate flow remain partly unresolved.
  • Governance·Compensation System (4/5): Shareholder returns and conventional governance support alignment, tempered by dependence on per-share capital management.
• 📊 Step 5 Score: 11/15 pts (Management Trust 4/5 + Insider Trends 3/5 + Governance·Compensation System 4/5)
• Step 5 Summary: Aflac’s management benefits from strong continuity, disciplined capital returns, and established insurance expertise. Insider activity is not a compelling positive signal, and long-term value creation still depends on sustainable underlying earnings.

⛵ Step 6: Aflac Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Aflac Guidance

• Consensus Earnings Outlook: Compiled estimates imply FY2026 EPS of approximately $7.02 and FY2027 EPS of approximately $7.62, representing 8.5% projected growth in the following fiscal year.
• Revenue Outlook: Estimated FY2026 revenue is approximately $16.94B, compared with $17.16B in FY2025, while FY2027 revenue is estimated at approximately $17.23B. This indicates a modest expected recovery rather than rapid growth.
• Guidance Comparison: A directly comparable management EPS or revenue guidance midpoint was not established for the same forecast definitions. The exact numerical guidance-to-consensus gap therefore cannot be calculated reliably.
• Analyst Positioning: The compiled average twelve-month price target was approximately $117.33, below the October 30 closing price. October analyst revisions were mixed, including a higher target from J.P. Morgan and reductions from several other firms.
• Sentiment Interpretation: Investors appear to recognize Aflac’s quality and shareholder distributions while remaining cautious about earnings growth and valuation.

Q6-A2. What Is Aflac’s Short Interest?

• Institutional Ownership: Approximately 69.24% of shares were institutionally held on the latest compiled ownership basis, indicating substantial professional-investor participation.
• Insider Ownership: Approximately 0.76% of shares were attributed to insiders.
• Free Float: Approximately 497.01M shares were classified as freely tradable, representing most outstanding common shares.
• Short Interest: A sufficiently current, consistently dated short-interest percentage and days-to-cover pair could not be confirmed from the retrieved records. The available information therefore does not support a quantified short-squeeze thesis.
• Market Flow Assessment: Aflac’s large free float and established institutional ownership are consistent with a liquid, mature insurance equity rather than a thinly traded speculative security.

Q6-A3. Step 6 Key Takeaways

• Scoring Rationale:
  • Consensus vs Guidance (2/3): Earnings expectations indicate modest growth and mixed analyst sentiment, but the precise comparison to management guidance is unavailable.
  • Supply·Short Interest (1/2): Broad institutional participation is established, while current short-interest and days-to-cover figures remain insufficiently verified.
• 📊 Step 6 Score: 3/5 pts (Consensus vs Guidance 2/3 + Supply·Short Interest 1/2)
• Step 6 Summary: Market expectations reflect a stable but slowly growing insurer. The upcoming earnings release is more important to the investment case than a speculative market-positioning catalyst.

🚀 Step 7: Aflac Catalysts & Price Triggers

Q7-A1. What Could Move Aflac Stock? (Top 3 Catalysts)

• 1 Q3 2026 Earnings and Underwriting Performance
  • Timing: November 4-5, 2026.
  • Success Conditions: Japan maintains strong pretax adjusted margins, U.S. benefit-ratio pressure moderates, and adjusted EPS confirms stable recurring earnings.
  • Failure Risk: Higher U.S. claims or weaker Japanese recurring premiums reduce adjusted earnings and trigger unfavorable estimate revisions.
• 2 Japanese Product Renewal and Sales Recovery
  • Timing: Next 6-12 months, assessed through quarterly insurance sales and persistency disclosures.
  • Success Conditions: Miraito, Anshin Palette, and Tsumitasu support stronger new annualized premiums and stabilize the mature Japanese in-force portfolio.
  • Failure Risk: New product sales fail to offset runoff, while persistency declines and the Japanese premium base contracts further.
• 3 Continued Buybacks and Dividend Growth
  • Timing: Next 6-12 months, subject to capital decisions and future quarterly disclosures.
  • Success Conditions: Sustainable subsidiary capital generation supports continued repurchases without reducing insurance solvency resilience.
  • Failure Risk: Investment losses, regulatory capital needs, or underwriting deterioration force management to reduce distributions.

Q7-A2. Aflac’s Earnings Revision Trend

• Forward Earnings Outlook: FY2027 compiled EPS of approximately $7.62 represents a projected recovery from FY2026’s $7.02. These are fiscal-year estimates rather than a verified sequence of upward revisions.
• Recent Analyst Changes: October 2026 target-price actions included both increases and reductions, providing no uniform evidence of strongly improving analyst confidence.
• Revision Interpretation: A complete comparable 90-day EPS estimate revision series was not established. The available evidence supports a neutral-to-cautious view rather than a documented sustained positive revision cycle.
• Key Confirmation Point: Q3 results must demonstrate whether Japanese margin improvements and U.S. earnings stabilization can support the projected FY2027 EPS recovery.

Q7-A3. Step 7 Key Takeaways

• Scoring Rationale:
  • Catalyst (5/7): Near-term earnings, Japanese product momentum, and continued capital returns provide credible catalysts, although their potential is moderate.
  • EPS Trend (2/3): Forward estimates indicate an earnings recovery, but a confirmed upward revision sequence is not established.
• 📊 Step 7 Score: 7/10 pts (Catalyst 5/7 + EPS Trend 2/3)
• Step 7 Summary: Aflac has identifiable earnings and capital-return catalysts, but their impact depends on stabilizing underlying insurance earnings. The next quarterly release will be particularly important.

⚖️ Step 8: Is Aflac Fairly Valued? Valuation Analysis

Q8-A1. Aflac’s Key Valuation Multiples

• PE Ratio: 13.22x (fairly valued) — GAAP earnings contain investment-related volatility and should not be treated as normalized recurring earnings.
• PS Ratio: 3.44x (fairly valued) — revenue multiples are secondary for insurers because underwriting margins and investment portfolio characteristics differ.
• PB Ratio: 2.05x (fairly valued) — supported by meaningful adjusted ROE, though asset marks and accumulated comprehensive income can affect comparability.
• P/TBV Ratio: 2.05x (fairly valued) — the standardized tangible-book ratio requires the same equity definition across comparison companies.
• P/FCF Ratio: N/A (unverifiable) — a comparable free-cash-flow multiple was unavailable, and conventional industrial FCF is not the primary valuation anchor.
• P/OCF Ratio: 23.46x (overvalued) — the relatively high multiple reflects weaker operating cash flow compared with accounting earnings.
• EV/Sales Ratio: 3.99x (fairly valued) — less informative for insurance operations because leverage and investable assets are integral to the business model.
• EV/EBITDA Ratio: 11.90x (fairly valued) — presented for completeness but carries limited weight relative to equity-based insurance valuation.
• EV/EBIT Ratio: 11.97x (fairly valued) — financing and insurance liability economics reduce comparability with industrial firms.
• EV/FCF Ratio: N/A (unverifiable) — no suitable consistent free-cash-flow enterprise multiple was established.
• Forward PE: 16.84x (overvalued) — the multiple is demanding relative to projected modest premium growth and normalized earnings development.
• PEG Ratio: 1.87x (fairly valued) — the metric depends on uncertain growth forecasts and is not decisive for a mature insurer.
• Scoring Rationale: Aflac’s reported trailing P/E appears moderate, but the normalized forward earnings multiple is more demanding while premium growth remains modest. Strong ROE and capital returns justify a quality premium, although they do not eliminate the limited prospective earnings yield.
• 📌 (1) Axis Q8-A1 Score: -2

Q8-A2. Aflac vs Peers: Valuation Comparison

• Multiple selection based on peer comparison: Forward P/E is the preferred comparison metric for supplemental insurance earnings, using Unum and MetLife as economically relevant reference companies while recognizing differences in product mix, geographic exposure, and capital structures.
• Calculation of peer-to-peer deviation rate: Not reliably quantifiable from the available comparable current forward-P/E observations.
  • 🧮 Calculation Formula: ((Aflac forward P/E 16.84x - comparable peer mean unavailable) / comparable peer mean unavailable) × 100 = not quantifiable.
• Scoring Rationale: Aflac’s forward multiple is established, but a synchronized, definition-consistent peer mean was not verified. The analysis does not assume that sector membership alone makes the two comparators’ earnings multiples directly equivalent.
• 📌 (2) Axis Q8-A2 Score: 0

Q8-A3. Is Aflac Cheap or Expensive vs Its History?

• Comparison Indicators: Price-to-book ratio, using five consecutive fiscal-year-end observations from FY2021 through FY2025, compared with the current October 2026 standardized multiple.
  • Historical Sample: FY2021 1.16x; FY2022 2.22x; FY2023 2.19x; FY2024 2.20x; FY2025 1.96x. Five annual endpoints spanning four years.
  • Observed Minimum: 1.16x.
  • Observed Maximum: 2.22x.
  • Current Multiple: 2.05x.
  • Range Position Calculation: (2.05 - 1.16) / (2.22 - 1.16) × 100 = 84.0%.
• Scoring Rationale: The current P/B multiple occupies the upper portion of the observed five-year annual-endpoint band. The comparison is sensitive to changing book equity, interest rates, and accounting marks, but it indicates a relatively demanding historical valuation rather than a compelling discount.
• 📌 (3) Axis Q8-A3 Score: -4

Q8-A4. What Growth Is Priced Into Aflac? (Reverse DCF)

• Implied Growth Rate: N/A
  • 1 Methodology: A simple discounted equity cash-flow model would require a defensible estimate of cash distributable from regulated insurance subsidiaries after claims, reserves, solvency capital, and reinvestment needs.
  • 2 Core assumptions: Reported operating cash flow is not interchangeable with shareholder-distributable cash for an insurer. The available capital-remittance and reserve sensitivity information does not establish a sufficiently reliable starting FCFE base.
• Achievable Growth Rate: N/A
  • Basis: Modest premium growth, investment income, and share repurchases provide earnings-growth evidence, but not a directly comparable distributable equity cash-flow growth rate.
• Growth gap and difficulty assessment:
  • 🧮 Formula: Achievable and implied growth rates cannot be meaningfully subtracted without a comparable distributable equity cash-flow base.
• Scoring Rationale: Aflac’s insurance reserve liabilities, subsidiary regulatory capital, and investment assets materially complicate the conversion of reported operating cash flow into FCFE. A multiple-based growth-hurdle assessment is more defensible than an unsupported cash-flow model.
• 📌 (4) Axis Q8-A4 Score: ➖

Q8-A4-1. What Growth Hurdle Does the Market Demand From Aflac? (Reverse DCF Alternative)

• Scoring Rationale: At approximately 16.84x forward earnings, Aflac needs stable underwriting performance, modest earnings growth, and continued shareholder distributions to support its current price. FY2027 EPS growth of approximately 8.5% would help justify the multiple, but it does not imply unusually substantial undervaluation or an extreme earnings hurdle.
• 📌 (4) Axis Q8-A4-1 Score: 0

Q8-A5. Aflac’s Hidden Asset & Stake Valuation

• Scoring Rationale: Not applicable — Aflac’s investment portfolio principally supports insurance liabilities and policyholder obligations, and no separately realizable asset or investment stake meeting the required valuation-materiality threshold was established independently of its operating insurance franchise.
• 📌 (5) Axis Q8-A5 Score: ➖

Q8-A6. Final Valuation Adjustment

• Scoring Rationale: Aflac’s mature insurance franchise, dividend growth, and buyback program are already reflected in the valuation and quality assessment. No distinct exceptional valuation factor supports a further adjustment.
• 📌 (6) Axis Q8-A6 Score: 0

Q8-A7. Valuation Adjustment Score Calculation

• Calculation Process:
  • (1) Axis (Key Valuation Indicators): -2 pts (Overvalued)
  • (2) Axis (Peer-to-peer deviation rate): 0 pts (Comparable peer deviation unavailable)
  • (3) Axis (Historical Band Position): -4 pts (observed-range position p = 84.0%; very overvalued)
  • (4) Axis (Justification for Growth): 0 pts (Forward earnings growth supports an appropriate valuation hurdle)
  • (5) Axis (Held assets·Share Valuation): 0 pts (Not applicable)
  • (6) Axis (Final adjustment): 0 pts (No separate exceptional factor)
• 📊 Valuation Adjustment Score: A1 (-2) + A2 (0) + A3 (-4) + A4 (0) + A5 (0) + A6 (0) = -6 pts
• Commentary: The valuation penalty primarily reflects a demanding position within Aflac’s historical price-to-book range and its forward earnings multiple. Stable underwriting, dividend growth, and repurchases support the stock’s quality characteristics but offer limited evidence of a substantial margin of safety at the prevailing price.
• Step 8 Summary: Aflac is a financially established insurer whose shares trade at a relatively demanding valuation compared with selected historical observations. Future performance depends on delivering normalized earnings growth rather than relying solely on a low reported trailing P/E.

💀 Step 9: What Are the Risks of Aflac? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to Aflac?

• 1 Japanese premium runoff and demographic pressure:
  • Cause: Japan’s mature insurance market, aging population, paid-up legacy policies, and replacement-product competition constrain recurring premium growth.
  • Impact: Persistent premium contraction could reduce the underwriting earnings base and eventually limit available capital for distributions.
  • Mitigation/Monitoring Indicators: Monitor Japanese net earned premiums in yen, new annualized premium sales, premium persistency, and product-level growth.
• 2 Deterioration in U.S. claims experience:
  • Cause: Higher benefit utilization, claims severity, or unfavorable product mix may outpace premium growth.
  • Impact: The U.S. benefit ratio rose to 49.5% in Q2 2026 from 47.3%, contributing to a decline in adjusted pretax profit margin to 20.9%.
  • Mitigation/Monitoring Indicators: Track quarterly benefit ratios, claims frequency, pricing actions, and adjusted pretax margins.
• 3 Investment portfolio and currency exposure:
  • Cause: Changes in credit conditions, interest rates, asset valuations, and the yen-dollar exchange rate affect investment earnings and reported results.
  • Impact: Significant investment losses or unfavorable currency movements could reduce equity, reported earnings, and parent-level capital flexibility.
  • Mitigation/Monitoring Indicators: Track credit losses, portfolio impairments, insurance solvency capital, and constant-currency adjusted earnings.

Q9-A2. How Sensitive Is Aflac to the Economy?

• 1 Sharp Yen Depreciation (Negative Impact ⬇): A weaker yen reduces the U.S.-dollar translation of Japanese operating income and can pressure consolidated reported earnings.
• 2 Rising Credit Spreads and Defaults (Negative Impact ⬇): Investment credit losses reduce earnings and may weaken available insurance capital, even if reinvestment yields increase.
• 3 Improving Interest Rates on New Fixed-Income Investments (Positive Impact ⬆): Higher reinvestment yields can increase portfolio income over time when asset-liability matching and credit quality remain controlled.

Q9-A3. Aflac Pre-Mortem: What Could Go Wrong?

• 1 Japan’s supplemental insurance franchise enters sustained contraction: New products fail to replace aging policies, persistency deteriorates, and the Japanese premium base shrinks enough to reduce recurring underwriting earnings.
  • Early Warning Signal: Multiple quarters of accelerating yen-denominated premium declines alongside weakening persistency and subdued new sales.
• 2 U.S. claims inflation overwhelms premium growth: Benefits increase materially faster than premiums, weakening adjusted operating margins and forcing underwriting or product changes.
  • Early Warning Signal: The U.S. benefit ratio continues rising while pretax adjusted margins fall for several successive quarters.
• 3 An investment credit shock reduces available capital: Material credit impairments or market disruptions pressure insurance capital and weaken the capacity to sustain elevated repurchases.
  • Early Warning Signal: Rising credit-loss provisions, worsening investment marks, declining capital ratios, and a material reduction in planned capital distributions.

Q9-A4. Risk Adjustment Score

• Reason for Scoring: Japan’s premium decline and the rise in the U.S. benefit ratio are observable operating concerns. Nevertheless, Japan’s improved adjusted margins, positive group operating cash generation, substantial equity, and continued shareholder distributions provide meaningful mitigants. The current evidence supports a manageable ongoing risk deduction rather than a demonstrated threat to insurance solvency or business continuity.
• 📊 Risk Adjustment Score: -4 pts
• Step 9 Summary: Aflac faces mature-market, claims, investment, and currency risks, but its diversified geographic earnings sources and established capital position provide resilience. Sustained underwriting deterioration would be more consequential than routine quarterly investment volatility.

🎯 Step 10: Aflac Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

• Investment Score Calculation Formula:
  • Step breakdown: S2 (20) + S3 (19) + S4 (16) + S5 (11) + S6 (3) + S7 (7) = 76 pts
  • Steps 2-7 Sum (76 pts) + Valuation Adjustment (-6 pts) + Risk Adjustment (-4 pts) = Investment Score 66 pts
• Investment Score & Rating: 66 pts (B Rating ⭐⭐⭐)
  • Commentary: Aflac’s established insurance franchises, adjusted profitability, and strong shareholder distributions support a solid fundamental assessment. The main constraints are weak underlying premium growth, uneven claims performance, and a relatively demanding historical valuation that reduces the margin of safety.

Q10-A2. Should You Buy Aflac? (Recommendation)

• Recommendation: Hold
  • Commentary: Aflac remains a credible long-term insurance and capital-return holding, but the current entry valuation offers limited compensation for modest organic earnings growth and Japanese premium exposure. Existing investors can monitor underwriting improvement and shareholder distributions, while new investors may benefit from a more favorable entry price.

Q10-A3. Investment Thesis in One Line

• Aflac offers durable supplemental insurance franchises, strong adjusted returns on equity, and disciplined shareholder distributions, but mature Japanese demand, U.S. claims pressure, and demanding valuation limit near-term upside.

Q10-A4. Aflac’s Price Trend & Key Drivers

• Stock Price Trend Over the Past 12 Months: Upward With Periodic Volatility 📈 — Aflac gained approximately 15.7% over the trailing twelve months through October 30, 2026, and traded near $123.89, below its 52-week high of $130.22. The latest month showed a meaningful recovery.
• October 2026 Renewed Insurance Sector and Aflac Share-Price Strength
  • Description: Aflac shares advanced during October ahead of its next earnings release, despite mixed analyst target revisions and expectations for modest fundamental growth.
  • Stock Price Reaction: Monthly Advance 📈 — The stock increased approximately 10.8% during October, although the movement cannot be attributed exclusively to any single company announcement.

Q10-A5. Action Plan

• Current Price: $123.89
• Buy Zone: $108.00 ($104.00–$112.00)
  • (1) Calculation of Fundamental Value: A conservative entry range emphasizes an earnings yield and price-to-book multiple more favorable than the current levels. At $104-112, Aflac would offer an improved margin of safety relative to its projected recurring earnings and historical valuation range.
  • (2) Momentum Premium/Discount Application: Recent positive price momentum does not justify an aggressive premium because recurring earnings growth remains modest and the near-term Q3 earnings catalyst introduces uncertainty.
  • (3) Conclusion: The $104.00-$112.00 range, centered on $108.00, offers a more attractive balance between Aflac’s business quality and the risks of mature-market earnings growth. The zone is a valuation-based entry range rather than a confirmed technical support level.
• Price Target: $121.92
• Expected Return: -1.6% (vs. current price)
  • 📍 Selected Valuation Metric: FY2027 projected diluted EPS multiplied by a normalized forward P/E — a suitable equity-based method for Aflac’s recurring insurance earnings, investment income, and capital structure.
  • 🧮 Price Target Calculation Formula: FY2027 projected EPS $7.62 × 16.0x forward P/E = $121.92
  • ⚓ Valuation Basis and Key Assumptions: The $7.62 FY2027 EPS input is compiled analyst consensus rather than company guidance, representing approximately 8.5% growth over projected FY2026 EPS of $7.02. The selected 16.0x multiple is an analytical judgment reflecting Aflac’s strong adjusted ROE, retention and capital returns, balanced against limited premium growth, geographic concentration, and claims exposure. It is slightly below the current 16.84x forward multiple because the present valuation already reflects much of the company’s quality. Unlike the historical P/B assessment, this target uses normalized future earnings rather than a trailing balance-sheet multiple; the resulting modest downside is consistent with constrained valuation upside.
• Conditions and timing for reaching price target: Over the next 6-12 months, beginning with the November 4 Q3 earnings announcement and subsequent quarterly results, stable Japanese underwriting margins, moderating U.S. claims pressure, and continued buybacks would support the base-case valuation. Materially stronger organic earnings could justify reassessment, while persistent deterioration would weaken it.
• Stop Loss: $95.00 ($93.00–$97.00)
• Action trigger upon catalyst achievement:
  • 1 Q3 earnings confirm improved U.S. underwriting
    • Description: A declining benefit ratio and stable adjusted margin would improve confidence in recurring earnings. Reassess valuation before adding at a premium. 👉 Maintain Holdings (Hold)
  • 2 Japan sales and premium persistency stabilize
    • Description: Stronger new sales and improved retention would reduce the principal structural concern and support a higher-quality earnings outlook. 👉 Consider Buying Within Buy Zone
  • 3 Buybacks remain substantial without weakening capital
    • Description: Continued share-count reduction supports per-share value, but its economic benefit depends on the repurchase valuation and sustainable subsidiary capital generation. 👉 Maintain Holdings (Hold)
• Action trigger upon risk realization:
  • 1 Japan premium contraction accelerates materially
    • Description: Repeated deterioration in premium volume and persistency would reduce confidence in the earnings base. 👉 Reduce Holdings (Sell)
  • 2 U.S. benefit ratio rises for multiple additional quarters
    • Description: Persistent claims inflation would threaten operating margins and lower sustainable adjusted EPS. 👉 Reduce Holdings (Sell)
  • 3 Investment losses materially weaken insurance capital
    • Description: A significant capital shortfall or forced reduction in shareholder distributions would undermine the capital-return investment case. 👉 Reduce Holdings (Sell)
• Customized Strategy Guide by Investment Preference:
  • Defensive Investors: Prioritize capital preservation and avoid initiating large positions near the current valuation. Consider entry only within the defined buy zone after reviewing the next earnings release.
  • Neutral Investors: Maintain existing exposure while monitoring Japanese premium retention and U.S. benefit ratios. Consider incremental purchases only when the valuation improves or earnings expectations strengthen materially.
  • Aggressive Investors: Use a staged entry approach within the buy zone and monitor quarterly claims, EPS revisions, and buybacks closely. Avoid treating price momentum alone as evidence of improving fundamentals.

🕵️‍♂️ Deep Dive Analysis

Q1: Is Aflac’s Dependence on Japan Its Biggest Long-Term Weakness?

• Analysis: Japan contributes roughly half of segment adjusted revenue and approximately two-thirds of positive operating-segment pretax adjusted earnings. Its high persistency and specialized insurance franchise create substantial stability, but mature demographics, legacy policy runoff, and yen exposure constrain growth. Q2 2026 yen-denominated premiums declined 3.7%, while Japan’s underwriting margin improved. This creates an important tension: profitability can remain strong even as the recurring premium base contracts.
• Judgment: Neutral to Negative — Japan’s contribution is an important competitive asset, but persistent premium erosion could eventually overwhelm underwriting efficiency improvements and slow long-term earnings compounding.

Q2: Can Aflac’s Forward P/E Near 17x Be Justified by Its Insurance Returns and Shareholder Distributions?

• Analysis: Aflac’s adjusted ROE of 16.6% in Q2 2026 supports a quality premium, while projected FY2027 EPS growth of approximately 8.5% offers a reasonable earnings recovery path. However, much of the earnings-per-share improvement depends on repurchases rather than rapid underlying premium expansion. The present forward multiple and elevated historical P/B range leave limited room for disappointment.
• Judgment: Fairly Valued to Slightly Overvalued — Strong capital efficiency supports the valuation, but the evidence does not establish a substantial discount to normalized intrinsic value.

Q3: Can Aflac’s Japanese Product Launches Reverse Premium Contraction?

• Analysis: Miraito, Anshin Palette, and the refreshed Tsumitasu offering broaden Aflac Japan’s product range and target evolving consumer insurance needs. H1 2026 new annualized premium sales increased 7.0% in yen, although Q2 sales declined 5.6% against a strong prior-year comparison. New sales must also compensate for aging policies, paid-up contracts, and reinsurance-related premium reductions before the existing premium base can stabilize.
• Judgment: Cautiously Positive — The product pipeline supports future sales opportunities, but evidence of sustainable in-force premium recovery remains incomplete.

Q4: Why Are Aflac’s GAAP Earnings Growing Faster Than Adjusted Earnings?

• Analysis: Q2 2026 GAAP net income rose 37.7%, while adjusted earnings declined 7.7%. Lower net investment losses materially improved reported results compared with the prior year. This demonstrates why insurance earnings require normalization for realized investment results, credit provisions, and currency-related movements. A single quarter of strong reported EPS does not necessarily indicate stronger underwriting fundamentals.
• Judgment: Neutral — The difference reflects important accounting and investment effects rather than a demonstrated breakdown in the operating franchise. Recurring adjusted earnings remain the more informative short-term performance measure.

Q5: Are Aflac’s Buybacks Creating More Value Than Organic Earnings Growth?

• Analysis: Aflac’s outstanding shares declined approximately 5.75% year over year, and Q2 repurchases totaled $983M. In H1 2026, adjusted earnings decreased 4.2% while adjusted EPS increased 2.0%. This illustrates how capital returns can produce per-share growth despite weaker aggregate earnings. Repurchases can be economically attractive when executed below intrinsic value, but purchasing shares at demanding multiples reduces the benefit to continuing shareholders.
• Judgment: Positive With Valuation Discipline — Aflac’s buybacks are a meaningful source of per-share compounding, but they cannot permanently substitute for sustainable underlying earnings growth.

Q6: Can Aflac’s U.S. Insurance Business Restore Underwriting Margins?

• Analysis: Q2 U.S. premiums increased 2.3%, but benefits and claims rose 7.0%. Consequently, the benefit ratio increased to 49.5%, while adjusted pretax margin declined to 20.9% from 22.5%. Improved sales and stable persistency alone are insufficient if claims costs continue to grow faster than premiums. Product repricing, underwriting discipline, and mix improvements are needed to restore margin momentum.
• Judgment: Neutral — The segment has growth opportunities, but sustained benefit-ratio stabilization is necessary before higher U.S. margins can be treated as a reliable earnings catalyst.

Q7: How Much Does Yen Volatility Affect Aflac’s Earnings Quality?

• Analysis: Japanese premiums and earnings are generated largely in yen, while consolidated financial reporting and U.S. shareholders evaluate results in dollars. A weaker yen can reduce translated results even when local underwriting economics remain stable. In Q2 2026, Japan’s yen-denominated pretax adjusted earnings increased 3.4%, while dollar-denominated pretax adjusted earnings declined 6.2%. This divergence illustrates why constant-currency analysis is essential.
• Judgment: Neutral to Negative — Currency fluctuations primarily introduce translation volatility, but prolonged movements and asset-liability mismatches can affect capital flexibility and reported returns.

Q8: Is Aflac’s Dividend Growth More Important Than Its Current Dividend Yield?

• Analysis: The current indicated yield is approximately 1.97%, which is not unusually high for an income-focused investor. However, the company’s long history of annual dividend increases and substantial repurchases creates a broader shareholder-return profile. Dividend sustainability depends on insurance subsidiary capital generation and earnings resilience, not solely on the present payout yield.
• Judgment: Positive — Dividend growth and buybacks together are more compelling than current cash yield alone, provided future capital distributions remain consistent with solvency and underwriting requirements.

Q9: Could Aflac’s Investment Portfolio Become a Bigger Risk Than Underwriting?

• Analysis: The investment portfolio is essential to Aflac’s business economics because premium proceeds are invested before future policyholder claims are settled. Credit losses, asset revaluation, duration mismatches, and reinvestment-rate changes can affect earnings and available capital. Q2 2026 included $77M of current expected credit losses and $11M of impairments among its investment-related adjustments. A broader credit downturn could create larger financial pressure.
• Judgment: Manageable but Material — Investment risk is a core feature of the insurance business, requiring continued monitoring of credit quality, asset-liability management, and solvency capital.

Q10: What Would Make Aflac a More Attractive Long-Term Investment Over the Next Year?

• Analysis: Three developments would materially strengthen the investment case: stabilization of Japanese yen-denominated earned premiums, improvement in U.S. benefit ratios, and sustained adjusted EPS growth driven by recurring operations rather than predominantly by repurchases. A more favorable entry valuation would further improve the prospective return profile. The November 2026 results and subsequent quarterly releases provide measurable opportunities to assess these conditions.
• Judgment: Constructive at a Better Entry Price — Aflac retains durable insurance franchises and strong shareholder distributions, but improved organic performance or a lower valuation would provide a clearer basis for new capital commitment.